Press releases
- Hansa Biopharma interim report January-March 2024
- Hansa Biopharma Expects Strong First Quarter 2024 Sales Performance
- Hansa Biopharma publishes 2023 Annual and Sustainability Reports
- Evan Ballantyne to join Hansa Biopharma as Chief Financial Officer
- Hansa Biopharma Year-end report January-December 2023
More ▼
Key statistics
On Friday, Hansa Biopharma AB (0RC7:LSE) closed at 27.15, 30.91% above the 52 week low of 20.74 set on Oct 13, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 27.38 |
---|---|
High | -- |
Low | -- |
Bid | 26.48 |
Offer | 27.82 |
Previous close | 27.13 |
Average volume | 4.64k |
---|---|
Shares outstanding | 52.67m |
Free float | 48.58m |
P/E (TTM) | -- |
Market cap | 1.43bn SEK |
EPS (TTM) | -16.07 SEK |
Data delayed at least 20 minutes, as of Apr 26 2024 17:51 BST.
More ▼